These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 21693271

  • 1. Suitable calcineurin inhibitor concentrations for liver transplant recipients in the Chinese population.
    Chen YB, Li SD, Ju BL, Shi XJ, Lu F, Hu DK, Yu CH, Dong JH.
    Transplant Proc; 2011 Jun; 43(5):1751-3. PubMed ID: 21693271
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
    Castroagudín JF, Molina E, Romero R, Otero E, Tomé S, Varo E.
    Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140
    [Abstract] [Full Text] [Related]

  • 4. Living donor liver transplant recipients achieve relatively higher immunosuppressant blood levels than cadaveric recipients.
    Trotter JF, Stolpman N, Wachs M, Bak T, Kugelmas M, Kam I, Everson GT.
    Liver Transpl; 2002 Mar; 8(3):212-8. PubMed ID: 11910565
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
    Fairbanks KD, Eustace JA, Fine D, Thuluvath PJ.
    Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Impaired erythropoietin production in liver transplant recipients: the role of calcineurin inhibitors.
    Bardet V, Junior AP, Coste J, Lecoq-Lafon C, Chouzenoux S, Bernard D, Soubrane O, Lacombe C, Calmus Y, Conti F.
    Liver Transpl; 2006 Nov; 12(11):1649-54. PubMed ID: 17058250
    [Abstract] [Full Text] [Related]

  • 9. The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients.
    Jain AK, Venkataramanan R, Shapiro R, Scantlebury VP, Potdar S, Bonham CA, Ragni M, Fung JJ.
    Liver Transpl; 2002 Sep; 8(9):841-5. PubMed ID: 12200788
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Elevated blood concentrations of calcineurin inhibitors during diarrheal episode in pediatric liver transplant recipients: involvement of the suppression of intestinal cytochrome P450 3A and P-glycoprotein.
    Maezono S, Sugimoto K, Sakamoto K, Ohmori M, Hishikawa S, Mizuta K, Kawarasaki H, Watanabe Y, Fujimura A.
    Pediatr Transplant; 2005 Jun; 9(3):315-23. PubMed ID: 15910387
    [Abstract] [Full Text] [Related]

  • 17. ACE gene D/D genotype as a risk factor for chronic nephrotoxicity from calcineurin inhibitors in liver transplant recipients.
    Gallon L, Akalin E, Lynch P, Rothberg L, Parker M, Schiano T, Abecassis M, Murphy B.
    Transplantation; 2006 Feb 15; 81(3):463-8. PubMed ID: 16477235
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.